UTHR Related Analyst Comments
-
Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
-
Canaccord Genuity Maintains a 'Hold' on United Therapeutics (UTHR); Increasing FY12 Adcirca and Tyvaso Revenues
-
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
-
Auriga Maintains a 'Hold' on United Therapeutics (UTHR); Q4 Review
-
United Therapeutics (UTHR) Lower As Analyst Highlights Sandoz Generic Remodulin Filing
-
Short Interest Ticks Up in Large-Cap Biotech, Specifically Amgen (AMGN)
-
Goldman Sachs Cuts Price Target on United Therapeutics (UTHR), But Still Sees 30% Upside
-
Goldman Sachs Sees Heavy Upside in United Therapeutics (UTHR) With Limited Risk
-
Citadel Securities Maintains a 'Neutral' on United Therapeutics (UTHR); Tyvaso Growth Returns, but We Remain Cautious Ahead of FREEDOM-C2 Data
-
Needham & Company Maintains a 'Buy' on Pluristem Therapeutics (PSTI); Enters into Early-Stage Licensing Agreement Around PLX Cells
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Citi 2Q10 SMID Biotech Earnings Preview: Adjusting AUXL & DNDN Models Ahead of Earnings; Top-Pick is BioMarin (BMRN)
-
Auriga Maintains Positive Stance On United Therapeutics (UTHR) Citing Strong Tyvaso Uptake
-
Auriga Maintains a 'Buy' on United Therapeutics (UTHR); Named as Best 2010 Biotechnology Idea
-
Wedbush Maintains a 'Neutral' on United Therapeutics (UTHR); Raises PT & Estimates
-
Wedbush Morgan Maintains an 'Outperform' on United Therapeutics (UTHR); Price Target Increased
-
Auriga Reiterates a 'Buy' on United Therapeutics (UTHR); Long-term Fundamentals Attractive
-
United Therapeutics (UTHR) Is Top Mid-Cap Pick at Deutsche Bank
-
Brean Murray raises its price target on United Therapeutics (UTHR) to $70
-
United Therapeutics (UTHR) option implied volatility at 51
-
CE Unterberg Towbin Issues Q3 Top Picks
Back to UTHR Stock Lookup
